The function of immunoglobulin A in immunity

Journal of Pathology

Volumn 208, Issue 2, 2006, Pages 270-282

  Woof, Jenny M ^a   Ken, Michael A ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Bacterial immunoglobulin binding proteins; Fc receptors; IgA; IgA deficiency; IgA nephropathy; IgA1 proteases; Mucosal immunity

Indexed keywords

CHOLERA VACCINE; FC RECEPTOR; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN RECEPTOR; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; ORAL POLIOMYELITIS VACCINE;

GASTROINTESTINAL TRACT; HUMAN; IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEPOSITION; MICROORGANISM; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYSTEM; REVIEW; UROGENITAL SYSTEM;

ANTIBODIES; ANTIGENS, CD; AUTOIMMUNE DISEASES; BACTERIAL INFECTIONS; BACTERIAL PROTEINS; HUMANS; IGA DEFICIENCY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A, SECRETORY; MODELS, MOLECULAR; MUCOUS MEMBRANE; RECEPTORS, FC; RECEPTORS, POLYMERIC IMMUNOGLOBULIN; SERINE ENDOPEPTIDASES;

EID: 31144457922     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.1877     Document Type: Review

References (119)

1. Chintalacharuvu KR, Raines M, Morrison SL. Divergence of human α-chain constant region gene sequences: a novel recombinant α2 gene. J Immunol 1994;152:5299-5304.
2. Tomana M, Niedermeier W, Mestecky J, Skvaril F. The differences in carbohydrate composition between the subclasses of IgA immunoglobulins. Immunochemistry 1976;13:325-328.
3. Mattu TS, Pleass RJ, Willis AC, Kilian M, Wormald MR, Lellouch AC, et al. The glycosylation and structure of human serum IgA1, Fab and Fc regions and the role of N-glycosylation on Fcα receptor interactions. J Biol Chem 1998;273:2260-2272.
4. Royle L, Roos A, Harvey DJ, Wormald MR, van Gijlswijk-Janssen D, Redwan El-RM, et al. Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems. J Biol Chem 2003;278:20 140-20 153.
5. Tarelli E, Smith AC, Hendry BM, Challacombe SJ, Pouria S. Human serum IgA1 is substituted with up to six O-glycans as shown by matrix assisted laser desorption ionisation time-of-flight mass spectrometry. Carbohydr Res 2004;339:2329-2335.
6. Munn EA, Feinstein A, Munro AJ. Electron microscope examination of free IgA molecules and of their complexes with antigen. Nature 1971;231:527-529.
7. Dourmashkin RR, Virella G, Parkhouse RME. Electron microscopy of human and mouse myeloma serum IgA. J Mol Biol 1971;56:207-208.
8. Boehm MK, Woof JM, Kerr MA, Perkins SJ. The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG: a study by X-ray and neutron scattering and homology modelling. J Mol Biol 1999;286:1421-1447.
9. Furtado PB, Whitty PW, Robertson A, Eaton JT, Almogren A, Kerr MA, et al. Solution structure determination of monomeric human IgA2 by X-ray and neutron scattering, analytical ultracentrifugation and constrained modelling: a comparison with monomeric human IgA1. J Mol Biol 2004;338:921-941.
10. Herr AB, Ballister ER, Bjorkman PJ. Insights into IgA-mediated immune responses from the crystal structures of human FcαRI and its complex with IgA1-Fc. Nature 2003;423:614-620.
11. Bastian A, Kratzin H, Eckart K, Hilschmann N. Intra- and interchain disulfide bridges of the human J chain in secretory immunoglobulin A. Biol Chem Hoppe Seyler 1992;373:1255-1263.
12. Atkin JD, Pleass RJ, Owens RJ, Woof JM. Mutagenesis of the human IgA1 heavy chain tailpiece that prevents dimer assembly. J Immunol 1996;157:156-159.
13. Krugmann S, Pleass RJ, Atkin JD, Woof JM. Structural requirements for assembly of dimeric IgA probed by site-directed mutagenesis of J chain and a cysteine residue of the α chain CH2 domain. J Immunol 1997;159:244-249.
14. Mostov KE, Friedlander M, Blobel G. The receptor for transepithelial transport of IgA and IgM contains multiple immunoglobulin-like domains. Nature 1984;308:37-43.
15. Hamburger AE, West AP, Bjorkman PJ. Crystal structure of a polymeric immunoglobulin binding fragment of the human polymeric immunoglobulin receptor. Structure 2004;12:1925-1935.
16. Frutiger S, Hughes GJ, Hanly WC, Kingzette M, Jaton JC. The amino terminal domain of rabbit secretory component is responsible for noncovalent binding to immunoglobulin A dimers. J Biol Chem 1986;261:16 673-16 681.
17. Geneste C, Iscaki S, Mangalo R, Pillot J. Both Fc alpha domains of human IgA are involved in in vitro interaction between secretory component and dimeric IgA. Immunol Lett 1986;13:221-226.
18. Hexham JM, White KD, Carayannopoulos LN, Mandecki W, Brisette R, Yang YS, et al. A human immunoglobulin (Ig) A Cα3 domain motif directs polymeric Ig receptor-mediated secretion. J Exp Med 1999;189:747-752.
19. Lewis MJ, Pleass RJ, Batten MR, Atkin JD, Woof JM. Structural requirements for the interaction of human immunoglobulin A with the human polymeric immunoglobulin receptor. J Immunol 2005;175:(in press).
20. Bakos M-A, Kurosky A, Goldblum RM. Characterization of a critical binding site for human polymeric Ig on secretory component. J Immunol 1991;147:3419-3426.
21. Bakos M-A, Kurosky A, Cwerwinski EW, Goldblum RM. A conserved binding site on the receptor for polymeric Ig is homologous to CDR1 of Ig V kappa domains. J Immunol 1993;151:1346-1352.
22. Coyne RS, Siebrecht M, Peitsch MC, Casanova JE. Mutational analysis of polymeric immunoglobulin receptor/ligand interactions. Evidence for involvement of multiple complementarity determining region (CDR)-like loops in receptor domain I. J Biol Chem 1994;269:31620-31625.
23. MacPherson AJ, Gatto D, Sainsbury E, Harriman G, Hengartner H, Zinkernagel RM. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science 2000;288:2222-2226.
24. Fagarasan S, Kinoshita K, Muramatsu M, Ikuta K, Honjo T. In situ class switching and differentiation to IgA-producing cells in the gut lamina propria. Nature 2001;413:639-643.
25. Boursier L, Gordon JN, Thiagamoorthy S, Edgeworth JD, Spencer J. Human intestinal IgA response is generated in the organized gut-associated lymphoid tissue but not in the lamina propria. Gastroenterology 2005;128:1879-1889.
26. Hanson LA, Korotkova M. The role of breastfeeding in prevention of neonatal infection. Semin Neonatol 2002;7:275-281.
27. Russell MW, Kilian M. Biological activities of IgA. In Mucosal Immunology (3rd edn), Mestecky J, Bienenstock J, Lamm ME, Mayer L, McGhee JR, Strober W (eds). Elsevier/Academic Press: Amsterdam, 2005; 267-289.
28. Roos A, Bouwman LH, van Gijlswijk-Jansen DJ, Faber-Krol MC, Stahl GL, Daha MR. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 2001;167:2861-2868.
29. Hamre R, Farstad IN, Brandtzaeg P, Morton HC. Expression and modulation of the human immunoglobulin A Fc receptor (CD89) and the Fc γ chain on myeloid cells in blood and tissue. Scand J Immunol 2003;57:506-516.
30. Kremer EJ, Kalatzis V, Baker E, Callen DF, Sutherland GR, Maliszewski CR. The gene for the human IgA Fc receptor maps to 19g13.4. Hum Genet 1992;89:107-108.
31. Morton HC, Pleass RJ, Storset AK, Brandtzaeg P, Woof JM. Cloning and characterization of equine CD89 and identification of the CD89 gene in chimpanzees and rhesus macaques. Immunology 2005;115:74-84.
32. Rogers KA, Scinicariello F, Attanasio R. Identification and characterization of macaque CD89 (immunoglobulin A Fc receptor). Immunology 2004;113:178-186.
33. Morton HC, Pleass RJ, Storset AK, Dissen E, Williams JL, Brandtzaeg P, et al. Cloning and characterization of an immunoglobulin A Fc receptor from cattle. Immunology 2004;111:204-211.
34. Maruoka T, Nagata T, Kasahara M. Identification of the rat IgA Fc receptor encoded in the leukocyte receptor complex. Immunogenetics 2004;55:712-716.
35. Ding Y, Xu G, Yang M, Yao M, Gao GF, Wang L, et al. Crystal structure of the ectodomain of human FcαRI. J Biol Chem 2003;278:27 966-27 970.
36. Woof JM, Burton DR. Human antibody-Fc receptor interactions illuminated by crystal structures. Nature Rev Immunol 2004;4:89-99.
37. Lang ML, Shen L, Wade WF. γ-chain dependent recruitment of tyrosine kinases to membrane rafts by the human IgA receptor FcαR. J Immunol 1999;163:5391-5398.
38. Lang ML, Chen YW, Shen L, Gao H, Lang GA, Wade TK, et al. IgA Fc receptor (FcαR) cross-linking recruits tyrosine kinases, phosphoinositide kinases and serine/threonine kinases to glycolipid rafts. Biochem J 2002;364:517-525.
39. Monteiro RC, van de Winkel JGJ. IgA Fc receptors. Annu Rev Immunol 2003;21:177-204.
40. Woof JM, van Egmond M, Kerr MA. Fc receptors. In Mucosal Immunology (3rd edn), Mestecky J, Bienenstock J, Lamm ME, Mayer L, McGhee JR, Strober W (eds). Elsevier/Academic Press: Amsterdam, 2005; 251-265.
41. van Spriel AB, Leusen JHW, van Egmond M, Dijkman HBPM, Assmann KJM, Mayadas TN, et al. Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunological synapse formation. Blood 2001;97:2478-2486.
42. van Spriel AB, Leusen JHW, Vile H, van de Winkel JGJ. Mac-1 (CD11b/CD18) as accessory molecule for FcαR (CD89) binding of IgA. J Immunol 2002;169:3831-3836.
43. Tsuge T, Shimokawa T, Horikoshi S, Tomino Y, Ra C. Polymorphism in promoter region of Fcα receptor gene in patients with IgA nephropathy. Hum Genet 2001;108:128-133.
44. Jasek M, Obojski A, Manczak M, Wisniewski A, Winiarska B, Malolepszy J, et al. Are single nucleotide polymorphisms of the immunoglobulin A Fc receptor gene associated with allergic asthma? Int Arch Allergy Immunol 2004;135:325-331.
45. Kaneko S, Kobayashi T, Yamamoto K, Jansen MD, van de Winkel JG, Yoshie H. A novel polymorphism of FcαRI (CD89) associated with aggressive periodontitis. Tissue Antigens 2004;63:572-577.
46. Shibuya A, Sakamoto N, Shimizu Y, Shibuya K, Osawa M, Hiroyama T, et al. Fcα/μ receptor mediates endocytosis of IgM-coated microbes. Nature Immunol 2000;1:441-446.
47. Sakamoto N, Shibuya K, Shimizu Y, Yotsumoto K, Miyabayashi T, Sakano S, et al. A novel Fc receptor for IgA and IgM is expressed on both hematopoietic and non-hematopoietic tissues. Eur J Immunol 2001;31:1310-1316.
48. Nakahara J, Seiwa C, Shibuya A, Aiso S, Asou H. Expression of Fc receptor for immunoglobulin M in oligodendrocytes and myelin of mouse central nervous system. Neurosci Lett 2003;337:73-76.
49. Monteiro RC, Moura IC, Launay P, Tsuge T, Haddad E, Benhamou M, et al. Pathogenic significance of IgA receptor interactions in IgA nephropathy. Trends Mol Med 2002;8:464-468.
50. Moura IC, Centelles MN, Arcos-Fajardo M, Malheiros DM, Collawn JF, Cooper MD, et al. Identification of the transferrin receptor as a novel immunoglobulin (Ig) A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med 2001;194:417-425.
51. Haddad E, Moura IC, Arcos-Fajardo M, Macher MA, Baudouin V, Alberti C, et al. Enhanced expression of the CD71 mesangial IgA1 receptor in Berger disease and Henoch-Schönlein nephritis: association between CD71 expression and IgA deposits. J Am Soc Nephrol 2003; 14:327-337.
52. Pasquier B, Lepelletier Y, Baude C, Hermine O, Monteiro RC. Differential expression and function of IgA receptors (CD89 and CD71) during maturation of dendritic cells. J Leuk Biol 2004;76:1134-1141.
53. Lamkhioued B, Gounni AS, Gruart V, Pierce A, Capron A, Capron M. Human eosinophils express a receptor for secretory component. Role in secretory IgA-dependent activation. Eur J Immunol 1995;25:117-125.
54. Motegi Y, Kita H. Interaction of secretory component stimulates effector functions of human eosinophils but not neutrophils. J Immunol 1998;161:4340-4346.
55. Mazanec MB, Nedrud JG, Kaetzel CS, Lamm ME. A three-tiered view of the role of IgA in mucosal defense. Immunol Today 1993;14:430-435.
56. Robinson JK, Blanchard TG, Levine AD, Emancipator SN, Lamm ME. A mucosal IgA-mediated excretory immune system in vivo. J Immunol 2001;166:3688-3692.
57. Gan Y-J, Chodosh J, Morgan A, Sixbey JW. Epithelial cell polarization is a determinant in the infectious outcome of immunoglobulin A-mediated entry by Epstein-Barr virus. J Virol 1997;71:519-526.
58. Yan H, Lamm ME, Bjorling E, Huang YT. Multiple functions of immunoglobulin A in mucosal defense against viruses: an in vitro measles virus model. J Virol 2002;76:10 972-10 979.
59. Zhang JR, Mostov KE, Lamm ME, Nanno M, Shimida S, Ohwaki M, et al. The polymeric immunoglobulin receptor translocates pneumococci across human nasopharyngeal epithelial cells. Cell 2000;102:827-837.
60. Mazanec MB, Kaetzel CS, Lamm ME, Fletcher D, Nedrud JG. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci USA 1992;89:6901-6905.
61. Mazanec MB, Coudret CL, Fletcher DR. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J Virol 1995;69:1339-1343.
62. Fujioka H, Emanicipator SN, Aikawa M, Huang DS, Blatnik F, Karban T, et al. Immunocytochemical colocalization of specific immunoglobulin A with Sendai virus protein in infected polarized epithelium. J Exp Med 1998;188:1223-1229.
63. Bomsel M, Heyman M, Hocini H, Lagaye S, Belec L, Dupont C, et al. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 1998;9:277-287.
64. Huang YT, Wright A, Gao X, Kulick L, Yan H, Lamm ME. Intraepithelial cell neutralization of HIV-1 replication by IgA. J Immunol 2005;174:4828-4835.
65. Kaetzel CS. The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces. Immunol Rev 2005;206:83-99.
66. Fallgren-Gebauer E, Gebauer W, Bastian A, Kratzin HD, Eiffert H, Zimmerman B, et al. The covalent linkage of secretory component to IgA. Structure of sIgA. Biol Chem Hoppe Seyler 1993;374:1023-1028.
67. Stewart WW, Kerr MA. The specificity of the human neutrophil IgA receptor (FcαR) determined by measurement of chemiluminescence induced by serum or secretory IgA1 or IgA2. Immunology 1990;71:328-334.
68. Hammerschmidt S, Talay SR, Brandtzaeg P, Chhatwal GS. SpsA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin A and secretory component. Mol Microbiol 1997;25:1113-1124.
69. Kilian M, Reinholdt J, Lomholt H, Poulsen K, Frandsen EV. Biological significance of IgA1 proteases in bacterial colonization and pathogenesis: critical evaluation of experimental evidence. APMIS 1996;104:321-338.
70. Polissi A, Pontiggia A, Feger G, Altieri M, Mottl H, Ferrari L, et al. Large-scale identification of virulence genes from Streptococcus pneumoniae. Infect Immun 1998;66:5620-5629.
71. Diebel LN, Liberati DM, Baylor AE, Brown WJ, Devlin J. Immunoglobulin A protease is a virulence factor for Gram-negative pneumonia. Surgery 2004;136:937-943.
72. Senior BW, Dunlop JI, Batten MR, Kilian M, Woof JM. Cleavage of a recombinant human immunoglobulin A2 (IgA2)-IgA1 hybrid antibody by certain bacterial IgA1 proteases. Infect Immun 2000;68:463-469.
73. Batten MR, Senior BW, Kilian M, Woof JM. Amino acid sequence requirements in the hinge of human immunoglobulin A1 (IgA1) for cleavage by streptococcal IgA1 proteases. Infect Immun 2003;71:1462-1469.
74. Senior BW, Woof JM. Effect of mutations in the human immunoglobulin A1 (IgA1) hinge on its susceptibility to cleavage by diverse bacterial IgA1 proteases. Infect Immun 2005;73:1515-1522.
75. Senior BW, Woof JM. The influences of hinge length and composition on the susceptibility of human IgA to cleavage by diverse bacterial IgA1 proteases. J Immunol 2005;174:7792-7799.
76. Chintalacharuvu KR, Chuang PD, Dragoman A, Fernandez CZ, Qiu J, Plant AG, et al. Cleavage of the human immunoglobulin A1 (IgA1) hinge region by IgA1 proteases requires structures in the Fc region of IgA. Infect Immun 2003;71:2563-2570.
77. Frithz E, Héden L-O, Lindahl G. Extensive sequence homology between IgA receptor and M proteins in Streptococcus pyogenes. Mol Microbiol 1989;3:1111-1119.
78. Stenberg L, O'Toole PW, Mestecky J, Lindahl G. Molecular characterization of protein Sir, a streptococcal cell surface protein that binds both immunoglobulin A and immunoglobulin G. J Biol Chem 1994;269:13458-13464.
79. Héden L-O, Frithz E, Lindahl G. Molecular characterization of an IgA receptor from group B streptococci: sequence of the gene, identification of a proline-rich region with unique structure and isolation of N-terminal fragments with IgA-binding capacity. Eur J Immunol 1991;21:1481-1490.
80. Jerlström PG, Chhatwal GS, Timmis KN. The IgA-binding beta antigen of the c protein complex of group B streptococci: sequence determination of its gene and detection of two binding regions. Mol Microbiol 1991;5:843-849.
81. Pleass RJ, Areschoug T, Lindahl G, Woof JM. Streptococcal IgA-binding proteins bind in the Cα2-Cα3 interdomain region and inhibit binding of IgA to human CD89. J Biol Chem 2001;276:8197-8204.
82. Langley R, Wines B, Willoughby N, Basu I, Proft T, Fraser JD. The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-FcαRI binding and serum killing of bacteria. J Immunol 2005;174:2926-2933.
83. Hammerschmidt S, Tillig MP, Wolff S, Vaerman J-P, Chhatwal GS. Species-specific binding of human secretory component to SpsA protein of Streptococcus pneumoniae via a hexapeptide motif. Mol Microbiol 2000;36:726-736.
84. Lu L, Lamm ME, Li H, Corthésy B, Zhang JR. The human polymeric immunoglobulin receptor binds to Streptococcus pneumoniae via domains 3 and 4. J Biol Chem 2003;278:48178-48187.
85. Elm C, Braathen R, Bergmann S, Frank R, Vaerman J-P, Kaetzel CS, et al. Ectodomains 3 and 4 of human polymeric immunoglobulin receptor (hpIgR) mediate invasion of Streptococcus pneumoniae into the epithelium. J Biol Chem 2004;279:6296-6304.
86. Hammarström L, Vorechovsky I, Webster D. Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID). Clin Exp Immunol 2000;120:225-231.
87. De la Concha EG, Fernandez-Arquero M, Gual L, Virgil P, Martinez A, Urcelay E, et al. MHC susceptibility genes to IgA deficiency are located in different regions on different HLA haplotypes. J Immunol 2002;169:4637-4643.
88. Castigli E, Wilson SA, Garibyan L, Rachid R, Bonilla F, Schneider L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nature Genet 2005;37:829-834.
89. Bogstedt AK, Nava S, Wadström T, Hammarström L. Helicobacter pylori infections in IgA deficiency: lack of role for the secretory immune system. Clin Exp Immunol 1996;105:202-204.
90. Robins G, Howdle PD. Advances in celiac disease. Curr Opin Gastroenterol 2005;21:152-161.
91. Fry L. Dermatitis herpetiformis: problems, progress and prospects. Eur J Dermatol 2002;12:523-531.
92. Sandborn WJ. Serologic markers in inflammatory bowel disease: state of the art. Rev Gastroenterol Disord 2004;4:167-174.
93. Hart AL, Stagg AJ, Frame M, Graffner H, Glise H, Falk P, et al. The role of the gut flora on health and disease, and its modification as therapy. Aliment Pharmacol Ther 2002;16:1383-1393.
94. Park J-H, Um J-I, Jin Lee B-J, Goh J-S, Park S-Y, Kim W-S, et al. Encapsulated Bifidobacterium bifudum potentiates intestinal IgA production. Cell Immunol 2002;219:22-27.
95. Brown WR. Liver and biliary tract. In Mucosal Immunology (3rd edn), Mestecky J, Bienenstock J, Lamm ME, Mayer L, McGhee JR, Strober W (eds). Elsevier/Academic Press: Amsterdam, 2005; 1371-1387.
96. van Egmond M, van Garderen E, van Spriel AB, Damen CA, van Amersfoort ES, van Zandbergen G, et al. FcαRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity. Nature Med 2000;6:680-685.
97. Launay P, Grossetete B, Arcos-Fajardo M, Gaudin E, Torres SP, Beaudoin L, et al. Fcα receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-IgA complexes in patients and CD89 transgenic mice. J Exp Med 2000;191:1999-2009.
98. Mestecky J, Tomana M, Crowley-Nowick PA, Moldoveanu Z, Julian BA, Jackson S. Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy. Contrib Nephrol 1993;104:172-182.
99. Allen AC, Harper SJ, Feehally J. Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol 1995;100:470-474.
100. Tomana M, Novak J, Julian BA, Matousovic K, Konecny K, Mestecky J. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 1999;104:73-81.
101. Xu L-X, Zhao M-H. Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy. Kidney Int 2005;68:167-172.
102. Novak J, Tomana M, Matousovic K, Brown R, Hall S, Novak L, et al. IgA1-circulating immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int 2005;67:504-513.
103. Monteiro, RC. New insights in the pathogenesis of IgA nephropathy. Nefrologia 2005;25:82-86.
104. Dechant M, Valerius T. IgA antibodies for cancer therapy. Crit Rev Oncol Hematol 2001;39:69-77.
105. Corthésy B. Recombinant secretory Immunoglobulin A in passive immunotherapy: linking immunology and biotechnology. Curr Pharm Biotechnol 2003;4:51-67.
106. Ma JK, Hikmat BY, Wycoff K, Vine ND, Chargelegue D, Yu L, et al. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nature Med 1998;4:601-606.
107. Janoff EN, Fasching C, Orenstein JM, Rubins JB, Opstad NL, Dalmasso AP. Killing of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement and phagocytes. J Clin Invest 1999;104:1139-1147.
108. van der Pol W, Vidarsson G, Vile HA, van de Winkel JG, Rodriguez ME. Pneumococcal capsular polysaccharide-specific IgA triggers efficient neutrophil effector functions via FcαRI (CD89). J Infect Dis 2000;182:1139-1145.
109. Vidarsson G, van der Pol W-L, van den Elsen JMH, Vilé H, Jansen M, Duijs J, et al. Activity of human IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B. J Immunol 2001;166:6250-6256.
110. Rodriguez ME, Hellwig SMM, Hozbor DF, Leusen J, van der Pol W-L, van de Winkel JGJ. Fc receptor-mediated immunity against Bordetella pertussis. J Immunol 2001;167:6545-6551.
111. Hellwig SMM, van Spriel AB, Schellekens JFP, Mooi FR, van de Winkel JGJ. Immunoglobulin A-mediated protection against Bordetella pertussis infection. Infect Immun 2001;69:4846-4850.
112. Stockmeyer B, Dechant M, van Egmond M, Tutt AL, Sundarapandiyan K, Graziano RF, et al. Triggering Fcα-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. J Immunol 2000;165:5954-5961.
113. van Egmond M, van Spriel AB, Vermeulen H, Huls G, van Garderen E, van de Winkel JGJ. Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of FcγRI (CD64) and FcαRI (CD89). Cancer Res 2001;61:4055-4060.
114. Dechant M, Vidarsson G, Stockmeyer B, Repp R, Glennie MJ, Gramatzki M, et al. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 2002;100:4574-4580.
115. Otten MA, Rudolph E, Dechant M, Tuk CW, Reijmers RM, Beelen RH, et al. Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J Immunol 2005;174:5472-5480.
116. Kauppi M, Eskola J, Kayhty H. Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccines. Paediatr Infect Dis J 1995;14:286-294.
117. Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J Infect Dis 1991;163:1-6.
118. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nature Med 2005;11:S45-S53.
119. Belshe RB. Current status of live attenuated influenza virus vaccine in the US. Virus Res 2004;103:177-185.